Home/Pipeline/AADvac1

AADvac1

Alzheimer's Disease

Phase 2Active

Key Facts

Indication

Alzheimer's Disease

Phase

Phase 2

Status

Active

Company

AXON Neuroscience

About AXON Neuroscience

AXON Neuroscience is a pioneering, privately-held biotech company at the forefront of tau-targeted therapies for Alzheimer's disease. Founded on the foundational tau research of Professor Michal Novák, the company has advanced its lead active immunotherapy candidate, AADvac1, through a successful Phase II clinical trial. With a deep scientific heritage and a specialized team, AXON is positioned as a key player in addressing one of medicine's largest unmet needs through its proprietary tau immunotherapy platform.

View full company profile

Therapeutic Areas

Alzheimer's Disease Neurodegenerative Disorders

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active